European Commission clears Lupin's eye treatment

Business Feb 23, 2026

Lupin just got the go-ahead from the European Commission for its new eye treatment, Ranluspec—a biosimilar version of ranibizumab.
It'll be available in both vials and pre-filled syringes, following a recent positive opinion from the Committee for Medicinal Products for Human Use.

Ranluspec works like existing treatments

Ranluspec is designed to help people with serious retinal diseases like age-related macular degeneration and diabetic eye problems.
Its approval came after a global trial, showing it works similarly to existing treatments by blocking unwanted blood vessel growth in the eye.

Sandoz to sell Ranluspec in most of Europe

Sandoz will handle selling Ranluspec across most of Europe (except Germany), with launches expected; timing not yet disclosed.
In France, they're teaming up with Biogaran.
Investors seem happy—Lupin's stock jumped 1.39% after the news.